Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charter Communications Inc (CHTR) vs Pfizer Inc (PFE) Price & Performance

Charter Communications IncTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Charter Communications Inc vs Pfizer Inc — how do they compare? Charter Communications Inc trades at $157.69 (market cap $18.28B), while Pfizer Inc trades at $26.61 (market cap $154.18B). The key difference: Pfizer Inc is far larger — about 8.4× Charter Communications Inc's market cap, and Pfizer Inc pays a 6.36% dividend while Charter Communications Inc pays none. Which is the better fit depends on your goals.

CHTRPFE
Market Cap
$18.28B$154.18B
Sector
MediaHealth
52-Week High
$282.74$28.56
52-Week Low
$123.31$23.60
Enterprise Value
$114.49B$205.67B
Volume
29,869,932
Dividend Yield
6.36%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charter Communications Inc

Charter Communications (CHTR) trades at $152.57, down 3.09% on the day, with a bullish technical signal from moving averages but mixed oscillators. The stock shows low valuation multiples with a P/E of 3.97 and P/S of 0.36, supported by a 9.05% net income margin and strong operating cash flow of $16.08B in 2025. Recent Q2 2026 earnings beat expectations with EPS of $10.66 versus $9.98 estimated, though revenue declined 1.7% year-over-year. News highlights debt refinancing activities and competitive pressures in broadband.

The outlook remains cautious due to subscriber losses and fiber competition, but the extreme valuation discount and aggressive buybacks offer potential upside. Risks include high debt leverage at $93.21B long-term and persistent industry headwinds. Analyst consensus is mixed with a $166.18 price target, suggesting 9% upside from current levels.

Pfizer Inc

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Charter Communications Inc

Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.

Read more on CHTR

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE